CONCORDBIO - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.9
| Stock Code | CONCORDBIO | Market Cap | 11,947 Cr. | Current Price | 1,142 ₹ | High / Low | 2,150 ₹ |
| Stock P/E | 37.6 | Book Value | 174 ₹ | Dividend Yield | 0.94 % | ROCE | 28.4 % |
| ROE | 21.4 % | Face Value | 1.00 ₹ | DMA 50 | 1,114 ₹ | DMA 200 | 1,351 ₹ |
| Chg in FII Hold | 0.21 % | Chg in DII Hold | -0.36 % | PAT Qtr | 70.2 Cr. | PAT Prev Qtr | 62.9 Cr. |
| RSI | 61.9 | MACD | -1.21 | Volume | 3,20,331 | Avg Vol 1Wk | 5,43,102 |
| Low price | 987 ₹ | High price | 2,150 ₹ | PEG Ratio | 1.40 | Debt to equity | 0.00 |
| 52w Index | 13.3 % | Qtr Profit Var | -5.20 % | EPS | 30.1 ₹ | Industry PE | 30.1 |
Analysis: Concord Biotech (CONCORDBIO) shows moderate fundamentals with ROCE of 28.4% and ROE of 21.4%. The debt-to-equity ratio is 0.00, which is a strong positive. Current price (1,142 ₹) is near DMA 50 (1,114 ₹), but below DMA 200 (1,351 ₹), suggesting downward pressure. RSI at 61.9 indicates slightly overbought conditions, while MACD (-1.21) signals weak momentum. Quarterly profit variation (-5.20%) is a concern despite overall PAT growth. Valuation is slightly higher than industry PE (37.6 vs 30.1), which limits upside potential.
Optimal Entry Price: Around 1,100–1,120 ₹ (near DMA 50 support).
Exit Strategy if Holding: Consider booking profits near 1,250–1,280 ₹ unless strong momentum develops toward 1,350 ₹ resistance.
✅ Positive
- Debt-free balance sheet (Debt-to-equity 0.00).
- Consistent PAT growth (70.2 Cr. vs 62.9 Cr.).
- EPS of 30.1 ₹ supports valuation strength.
- FII holdings increased (+0.21%), showing foreign investor confidence.
⚠️ Limitation
- Quarterly profit variation of -5.20% raises caution.
- Trading below DMA 200 indicates weak long-term trend.
- DII holdings decreased (-0.36%), showing reduced domestic interest.
- Valuation premium with P/E above industry average.
📰 Company Negative News
- No major negative news reported, but profit decline in recent quarter is a concern.
🌟 Company Positive News
- Strong PAT growth quarter-on-quarter.
- Debt-free status enhances financial flexibility.
- Foreign investor interest has increased.
🏭 Industry
- Industry P/E at 30.1 suggests Concord Biotech trades at a premium.
- Biotech sector remains promising but volatile, with high growth potential.
📌 Conclusion
Concord Biotech is a moderately strong candidate for swing trading. Entry around 1,100–1,120 ₹ offers a favorable setup, while exit near 1,250–1,280 ₹ is optimal unless momentum strengthens toward 1,350 ₹. Debt-free status and PAT growth are positives, but valuation premium and profit variation warrant cautious optimism.
Would you like me to expand this with a technical chart outlook, peer comparison, or sector growth analysis?